Novartis' Zelnorm For Chronic Constipation Recommended With Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients over the age of 65 and males should be excluded from treatment with Zelnorm (tegaserod) for chronic constipation, FDA gastrointestinal advisory committee says. Concerns about the risk of ischemic colitis and severe diarrhea, and lack of efficacy, in older patients were cited by committee members.